Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Open original sourceLoading market dashboard
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Open original source